Avacc 2
Alternative Names: Avacc-2Latest Information Update: 26 Mar 2024
At a glance
- Originator Intravacc
- Class Enterovirus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Coxsackievirus infections; Enterovirus A infections
Most Recent Events
- 27 Feb 2024 Avacc 2 is available for licensing as of 27 Feb 2024. https://www.intravacc.nl/services/pipeline
- 27 Feb 2024 Preclinical trials in Coxsackievirus infections (Prevention) in Netherlands (IM), prior to February 2024 (Intravacc pipeline, February 2024)
- 27 Feb 2024 Preclinical trials in Enterovirus A infections (Prevention) in Netherlands (IM), prior to February 2024 (Intravacc pipeline, February 2024)